工程化TYK2依赖性使IL-10在髓系细胞中选择性激活
Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism
研究发现髓系细胞和T细胞对IL-10信号传导依赖TYK2的程度不同,开发了一种选择性IL-10R激动剂msIL-10R,能够在不激活T细胞的情况下抑制炎症。
该研究揭示了IL-10在不同免疫细胞中依赖TYK2的信号传导差异,为开发选择性免疫调节剂提供了新思路。
译文尚不完整,完整内容请切换到原文。
Main
IL-10 是一种强效的抗炎细胞因子,有助于维持免疫耐受1,6。 IL10 或其受体 IL10RA (编码 IL-10Rα)和 IL10RB (编码 IL-10Rβ)的功能丧失性突变会导致早发型炎症性肠病(IBD)和自身炎症性疾病1,7。当 IL-10 与 IL-10Rα 和 IL-10Rβ 结合并形成四聚体受体复合物时,即启动 IL-10 信号传导,该复合物分别组成型地与 Janus 激酶 1(JAK1)和酪氨酸激酶 2(TYK2)结合1,8。这种结合触发依赖 JAK1 的 IL-10Rα 磷酸化以及信号转导及转录激活因子 3(STAT3)磷酸化,从而抑制促炎基因表达并促进免疫耐受8,9。IL-10 主要通过抑制细胞因子产生、抗原呈递和 T 细胞致敏,在髓系细胞和抗原呈递细胞(如树突状细胞 [DCs] 和巨噬细胞)中发挥其主要耐受诱导作用5,10,11,12,13。这些细胞中 IL10RA 或 STAT3 的缺失会导致结肠炎和系统性炎症10,12,13。
尽管 IL-10 在免疫耐受中起着核心作用,但其双重功能严重限制了其治疗应用6,14。虽然 IL-10 能强效抑制髓系细胞中的炎症,但较高浓度会激活 T 细胞,促进 IFNγ 依赖的髓系造血,并减少血小板和红细胞计数2,4,5,15。在克罗恩病和银屑病中的早期临床试验显示其治疗窗口狭窄,因无意中激活 T 和 B 细胞而导致剂量限制性贫血和血小板减少症5,14。相反,其增强细胞毒性 T 细胞功能和辅助性 T 细胞 1 型(TH1)细胞分化的能力推动了聚乙二醇化 IL-10 作为针对实体瘤的癌症免疫治疗药物的开发16。然而,IL-10 有限的治疗指数,源于这些相反的免疫抑制和免疫刺激作用以及血液学毒性,仍然是一个主要障碍16,17,18。之前工程化选择性 IL-10 变体的尝试受到短半衰期、免疫原性以及有益和有害活性分离不完全的限制14,19,20。
IL-10 中的细胞特异性 TYK2 依赖性
JAK 家族激酶的激活需要受体介导的二聚化,以允许反式磷酸化21,22。天然 IL-10 是一个结构域互换的二聚体19,23,它组装成 (IL-10Rα)2–(IL-10Rβ)2 信号复合物,通过 TYK2–JAK1 和 JAK1–JAK1 反式磷酸化通路使 JAK1 激活成为可能21,22,23(图. 1a)。JAK1 对于 IL-10Rα 磷酸化和下游 STAT3 激活是必需的9(扩展数据图. 1a,b)。
a,IL-10单体及二聚体通过JAK1–JAK1和TYK2–JAK1反式磷酸化介导信号传导的模式图。b,经PBS或IL-10处理的野生型(WT)或TYK2缺陷型BMDM中pSTAT3的平均荧光强度(MFI),处理时在DMSO、VVD-118313(VVD)或upadacitinib(UPA)存在下(n = 3个生物重复)(左侧)。右侧,IL-10及所示抑制剂处理的LPS刺激BMDM上清液中的TNF浓度(n = 5或6个生物重复,来自两项实验的合并数据)。c,人血单核细胞在TYK2抑制剂存在或缺失下经IL-10刺激的pSTAT3 MFI(n = 3名供者)。d,IL-10处理、TYK2抑制剂存在或缺失的LPS刺激人PBMC上清液中的TNF和IL-6浓度(n = 3名供者)。e,IL-10处理、TYK2抑制剂存在或缺失的CD8+ T细胞中pSTAT3 MFI。插图:TYK2抑制剂处理细胞的放大视图;基线表示未刺激水平。n = 3名供者。f、h,靶向所示基因或非靶向对照(NTC)的CRISPR编辑CD8+ T细胞经IL-10刺激后的pSTAT3(f)和granzyme B(h)MFI。n = 3名供者。g,IL-10处理、TYK2抑制剂存在或缺失的CD8+ T细胞上清液中granzyme B和IFNγ浓度,以无IL-10细胞为基准归一化。n = 3名供者。FC,倍数变化。i–k,滴定浓度IL-10或IL-10单体处理的单核细胞及T细胞中pSTAT3 MFI(i)、LPS刺激PBMC上清液中TNF和IL-6浓度(j),以及活化CD8+ T细胞上清液中granzyme B和IFNγ浓度(k)。n = 3名供者。除非另有说明,IL-10使用浓度为10 nM。数据为均值 ± 标准差。点代表生物重复。统计分析采用双尾非配对t检验(c–e 和g)及带Dunnett多重比较检验的单因素方差分析(ANOVA)(b、f和h);*P < 0.05,**P < 0.01,***P < 0.001,****P < 0.0001;NS,无显著性。
为解析这些信号通路,我们使用了选择性别构JAK1抑制剂(VVD-118313),其靶向小鼠C816并选择性阻断JAK1反式磷酸化,而不抑制激酶结构域22。在骨髓来源巨噬细胞(BMDMs)中,VVD-118313介导的JAK1–JAK1反式磷酸化抑制部分降低了IL-10诱导的STAT3磷酸化,但未完全阻断功能性反应,这与TYK2介导反式磷酸化的代偿作用一致(图1b及扩展数据图1c–e)。在TYK2缺陷型BMDMs中,VVD-118313完全阻断了STAT3磷酸化和IL-10功能,表明至少一条反式磷酸化通路(JAK1–JAK1或TYK2–JAK1)必须保持完整才能维持信号传导能力。作为对照,ATP竞争性JAK1激酶抑制剂(upadacitinib)完全阻断了IL-10介导的STAT3磷酸化及LPS诱导的TNF和IL-6抑制(图1b及扩展数据图1c–e)。
与小鼠骨髓衍生巨噬细胞(BMDM)中的这些发现一致,使用扎索替尼(zasocitinib)对 TYK2 进行药理学抑制,在人类单核细胞中部分减少了 IL-10 驱动的 STAT3 磷酸化(图.1c,扩展数据图.1f 和补充图.2),但并未损害初级外周血单个核细胞(PBMC)中脂多糖(LPS)诱导的 TNF 和 IL-6 的功能性抑制(图.1d)。作为对照,扎索替尼完全阻断了 IL-23 和 IFNα 诱导的 STAT3 磷酸化及下游信号传导(扩展数据图.2a)。CRISPR 介导的人类巨噬细胞 TYK2 敲除产生了类似的结果(扩展数据图.2b,c),证实 TYK2 对于巨噬细胞中 IL-10 介导的 TNF 和 IL-6 抑制是非必需的24。
相比之下,TYK2 抑制剂和 CRISPR 敲除均降低了 CD8+ T 细胞中 IL-10 诱导的 STAT3 磷酸化(图.1e,f 和扩展数据图.1g 及 2d),并完全消除了穿孔素 B 和 IFNγ 产生的增强作用(图.1g,h),表明 T 细胞对 TYK2 具有严格依赖性。
我们接下来测试了调节信号幅值是否能利用这种差异化的激酶依赖性。一种工程化 IL-10 单体19,其结合单一的 IL-10Rα–IL-10Rβ 异源二聚体(图.1a),将信号限制在单一的 TYK2–JAK1 反式磷酸化途径中(扩展数据图.2e–h)。该单体在血液单核细胞中诱导了约 50% 最大值的 STAT3 磷酸化,但仍保留了显著的 TNF 抑制和部分 IL-6 抑制作用(图.1i,j)。在 T 细胞中,该单体未诱导 STAT3 磷酸化(图.1i,扩展数据图.1g 和补充图.2),也未增加 IFNγ 和穿孔素 B 的产生(图.1k)。这些数据表明不同细胞类型之间存在不同的阈值:髓系细胞耐受衰减的输入,而 T 细胞需要最大信号,从而使得具有衰减激动剂的天然髓系选择性成为可能。
总体而言,这些观察结果表明,天然免疫细胞类型特异性的 TYK2 依赖性,结合信号强度的调节,可以利用来产生选择性 IL-10 激动剂,从而将髓系免疫抑制与 T 细胞刺激解偶。
髓系选择性 IL-10R 激动剂
虽然衰减配体如 IL-10 单体和亲和力调节的 IL-10 突变体在体外提供了髓系选择性的概念验证20,但其治疗潜力受限于对天然存在的抗 IL-10 自身抗体的易感性25、热不稳定性、TNF 和 IL-6 抑制效力降低(图.1j)以及残留的 T 细胞和 B 细胞激活20。为了克服这些限制并实现对 IL-10R 信号的精确控制,我们采用了单域抗体(纳米抗体)方法。纳米抗体因其小尺寸(12–14 kDa)、高亲和力和有利的可开发性特性26,非常适合用于受体激动。
羊驼用人类 IL-10Rα 胞外域(ECD)、IL-10Rβ ECD 或 IL-10Rα–IL-10Rβ 异二聚体 Fc 融合蛋白进行免疫(图 2a)。源自 B 细胞的可变重链域(VHH)库用于构建噬菌体库,并从中分离出多种抗 IL-10Rα 和抗 IL-10Rβ VHH 家族(补充表 1 和 2)。将 VHH 对组装为二聚体 6×His 标签或四聚体 Fc 融合蛋白,其中 N 端定位抗 IL-10Rα 或抗 IL-10Rβ,并使用表达 IL-10Rα–IL-10Rβ 的 STAT3 报告细胞系进行筛选(图 2b)。
a,羊驼使用人类 IL-10Rα、IL-10Rβ 或 IL-10Rα–IL-10Rβ 异二聚体 Fc-融合蛋白免疫的示意图,随后构建 VHH 噬菌体库并筛选四价 IL-10R 激动剂。b,在稳定表达 IL-10Rα 和 IL-10Rβ 的 HEK293T 细胞中,使用 STAT3–荧光素酶报告基因检测法筛选四价纳米抗体候选物。c,msIL-10R 激动剂的设计。d,IL-10、msIL-10R 激动剂或全 IL-10R 激动剂处理 LPS 刺激的人类 PBMC 中 IL-6 和 TNF 的剂量依赖性抑制。 n = 3 名供体。曲线代表对剂量–反应数据的四参数非线性回归拟合。 e,用所示激动剂处理抗 CD3/CD28 刺激的 CD8+ T 细胞 3 天后 IFNγ 的剂量依赖性诱导。 n = 3 名供体。曲线代表对剂量–反应数据的四参数非线性回归拟合。 f,用 IL-10 或 msIL-10R 激动剂处理 15 分钟后全血中单核细胞和 CD8+ T 细胞的 pSTAT3 MFI。 n = 2 名供体。 g,人类 PBMC 用 PBS、10 nM IL-10–Fc 或 msIL-10R 激动剂处理 24 h,在无(左)或有(右)1 ng ml−1 LPS 存在下的 RNA-seq 分析。 n = 3 名供体。比较 IL-10–Fc 和 msIL-10R 激动剂的差异基因表达(相对于 PBS 的 log2 转换倍数变化)。 h,用 IL-10–Fc(左)或 msIL-10R 激动剂(右)处理 24 h 后活化 CD8+ T 细胞相对于 PBS 的差异基因表达。 n = 3 名供体。使用 edgeR 分析差异表达;使用双侧拟似然 F 检验结合 Benjamini–Hochberg FDR 校正确定显著性。所有数据均为所示的生物学重复。数据为平均值 ± 标准差。a 和 c 中的示意图使用 BioRender 制作;Yi, T. https://biorender.com/juf8dyp (2026)。
在测试的 882 种组合中,182 种构建体表现出 STAT3 报告活性,21 个分子在 LPS 刺激的人类 PBMC 中实现了超过 90% 的 TNF 抑制和超过 85% 的 IL-6 抑制(补充图 3)。然而,大多数四价 IL-10R 激动性纳米抗体在 CD8+ T 细胞分泌 IFNγ 和穿孔素 B 增加方面重现了天然 IL-10 的部分 T 细胞刺激谱,全 IL-10R 激动剂即为典型例证(补充图 4),突显了实现功能选择性的挑战。
选择性及效力高度依赖于克隆。一种四价构建体(图2c)展现出皮摩尔级效力,并近乎完全具备髓系选择性:在人外周血单个核细胞(PBMCs)中,其脂多糖(LPS)诱导的 TNF 半最大抑制浓度(IC50)为 2.1 pM,IL-6 为 6.9 pM,且未显著诱导 T 细胞 IFNγ 产生或 B 细胞增殖(图2d,e及扩展数据图3a–d)。我们将该分子命名为髓系选择性 IL-10R 激动剂(以下简称 msIL-10R 激动剂)。表面等离子共振(SPR)分析证实其与人 IL-10Rα(KD = 2.8 nM)及 IL-10Rβ(KD = 1.1 nM)具有高亲和力结合,且相对于天然 IL-10,其对 IL-10Rβ 的亲和力显著更高(补充图5及补充表3)。
与亲和力减弱、偏向髓系的 IL-10 钝变蛋白20相比,msIL-10R 激动剂展现出更佳的淋巴细胞选择性(扩展数据图3a–d)。IL-10 钝变蛋白 10DE 和 D25K 在 T 细胞中保留了约 30% 的最大 STAT3 磷酸化水平并诱导 IFNγ 产生20,而 msIL-10R 激动剂在 CD4+ T 细胞和 CD8+ T 细胞中仅引起微弱的信号传导(<10% Emax)(图2f、扩展数据图3a–c及补充图6),且未诱导细胞毒性效应程序(图2e及扩展数据图3c)。此外,与 IL-10 及 IL-10 钝变蛋白不同,msIL-10R 激动剂在 B 细胞中几乎不引起 STAT3(pSTAT3)磷酸化(扩展数据图3a,b),且不促进 B 细胞扩增或浆母细胞分化(扩展数据图3d),表明其在各类淋巴细胞群体中选择性均有改善。
RNA 测序(RNA-seq)的转录组谱分析显示,在静息及 LPS 刺激的人外周血单个核细胞中,IL-10、IL-10–Fc 与 msIL-10R 激动剂引发的转录响应高度相关,包括对 CSF3、IL6 及 PTGES 等炎症基因的 comparable 抑制作用(图2g及补充图7)。相比之下,仅在激活的 T 细胞培养物中,IL-10 和 IL-10–Fc 诱导了细胞毒性 T 细胞相关基因(如 GZMB 和 BCL6)的表达,而 msIL-10R 激动剂在 T 细胞中未诱导任何显著差异表达基因(图2h及补充图8)。
综上所述,通过对约 1,000 种四价纳米抗体组装体的经验性高通量筛选,我们鉴定出一种 msIL-10R 激动剂,它在髓系细胞中重现了 IL-10 的抗炎程序,同时解偶联了其在淋巴细胞中的免疫刺激效应。
IL-10R 激动作用的结构基础
msIL-10R 激动剂由串联 VHH 结构域融合至 Fc 支架组成,每条臂包含一个抗-IL-10Rα VHH(克隆 E07)与一个抗-IL-10Rβ VHH(克隆 A05)(以下简称 E07-A05)(图2c)。为明确其受体结合模式,我们解析了 IL-10Rα 细胞外结构域(ECD)和 IL-10Rβ ECD 与 E07-A05 串联 VHH 复合物的冷冻电镜(cryo-EM)结构。
由于受体–VHH 复合物(约 78 kDa)尺寸较小,在冷冻电镜研究中,我们使用了近期开发的一种抗 VHH 示踪 Fab(NabFab;Fab 1)以促进颗粒对齐和重建27。NabFab 识别 VHH A05 中位于 E07-A05 连接子远端的工程化结合表位,且不影响所有 CDR 及生物活性(扩展数据图 4 和补充图 9)。IL-10Rα–IL-10Rβ–E07-A05 复合物的冷冻电镜图谱整体分辨率为 3.14 Å(图 3a 和补充图 10)。局部分辨率从 IL-10Rβ–VHH A05 界面的 2.8 Å 到 IL-10Rα–VHH E07 界面的约 4 Å 不等,表明受体结合模块之间存在构象柔性。为进一步定义 E07 表位,我们测定了去糖基化 IL-10Rα ECD 与 E07 及抗 VHH Fab(Fab 2)复合物在 2.40 Å 分辨率下的第二种冷冻电镜结构(图 3b 和补充图 11)。整合这些数据集生成了完整受体结合组装体的复合分子模型(图 3c)。
a,与抗 VHH Fab 1 结合的 IL-10Rα–IL-10Rβ–E07-A05 串联 VHH 复合物的冷冻电镜密度图,分辨率为 3.14 Å。b,与抗 VHH Fab 2 结合的 IL-10Rα–VHH E07 复合物的冷冻电镜密度图,分辨率为 2.40 Å。c,IL-10Rα–IL-10Rβ–E07-A05 受体复合物的复合结构模型。d,与 VHH A05 或 IL-10–IL-10Rα(PDB: 6X93)复合的 IL-10Rβ 结构叠加。e,IL-10Rβ–VHH A05 结合界面的详细视图,高亮显示受体接触点及 Asn138–Trp143 环的构象重排。f,IL-10Rα–VHH E07 结合界面的详细视图。E07 结合跨越 IL-10Rα 两个 III 型纤维连接蛋白结构域之间连接处的表位。 g,IL-10Rα–IL-10Rβ–E07-A05(位于粉色虚线框内)与 IL-10Rα–IL-10Rβ–IL-10(PDB: 6X93,位于黑色点线框内)受体复合物的叠加。位于 IL-10Rα–IL-10 界面的疾病相关 IL-10Rα 突变 Y64C 和 R117C/H 以橙色显示;其他 IBD 相关变异体(W45G、T84I、L90P、Y91C、R101W、L125R、L132R、G141R、I169T、F190C 和 C223R/S)以黄色显示。h,在 LPS 刺激下,表达野生型或指定人源 IL-10Rα 变异体并在存在 IL-10、IL-10 突变体(10DE 和 D25K)或 msIL-10R 激动剂(浓度为 0.1 nM、1 nM 和 10 nM)的情况下,胞内 TNF 阳性的 RAW264.7 细胞的百分比。数据为均值 ± 标准差。n = 3 个生物学重复。统计分析采用单因素方差分析配合 Dunnett 多重比较检验进行。
与由 IL-10、IL-22 和 IFNλ 形成的受体复合物相比,msIL-10R 激动剂诱导了独特的受体组织方式23,28,29(图 3c,d 和扩展数据图 5)。VHH A05 结合到 IL-10Rβ 上的一个表位,该表位与 IL-10 家族细胞因子使用的细胞因子结合表面部分重叠。然而,A05 的结合诱导了 IL-10Rβ 的 Asn138–Trp143 环的局部构象重排,将 Trp143 和 Tyr140 定位到由 VHH A05 的 CDR2 和 CDR3 形成的裂缝中(图 3e)。涉及 CDR2 和 CDR3 的额外接触生成广泛的相互作用网络,稳定了受体结合(图 3e)。
相比之下,VHH E07 识别 IL-10Rα 串联纤维连接蛋白 III 型结构域之间接合处的一个大表面(图 3f)。该表位位于 IL-10 结合位点的对面,且与与炎症性肠病(IBD)相关的已知疾病相关 IL10RA 突变不接触30(图 3g)。与此观察一致的是,IL-10Rα 中与疾病相关的 IL-10 结合界面突变(R117C、R117H 和 Y64C)显着削弱了天然 IL-10 对 TNF 的抑制作用,并对亲和性调节的 IL-10 嵌合体的抑制作用削弱程度更大(图 3h)。相比之下,msIL-10R 激动剂在表达这些疾病相关 IL10RA 变体的细胞中保留了完全活性(图 3h)。
为了确定激动活性的结构决定因素,我们通过将结合破坏性突变引入 E07 或 A05 中,选择性地破坏了受体结合。无论是 *cis * 还是 *trans*,IL-10Rα 或 IL-10Rβ 结合的丧失均显着降低了 STAT3 磷酸化并削弱了对促炎细胞因子的抑制,包括 TNF、IL-6 和 IL-1β(扩展数据图 6a–c)。最大效力和效能需要同时间接交联两个 IL-10Rα 分子与一个或两个 IL-10Rβ 分子(扩展数据图 6a–c),表明四价结构对于完全的激动剂活性至关重要。
重要的是,激动活性和髓系选择性对分子几何形状高度敏感。改变 E07 和 A05 之间的连接臂长度,无论是缩短还是延长 GS 连接臂,均大幅降低了活性(扩展数据图 6d)。同样,逆转串联 VHH 的拓扑结构完全消除了信号传导。尽管先导化合物 E07-A05/E07-A05 构建体作为强效的髓系选择性 IL-10R 激动剂起作用,但拓扑倒置的 A05-E07/A05-E07 构建体在 STAT3 报告基因检测中没有检测到活性(扩展数据图 6e)。值得注意的是,具有对称结构的构建体(A05-A05/E07-E07)增加了 pSTAT3 活性并增强了髓系活性,但也恢复了 T 细胞激活,诱导了约 20% 由天然 IL-10 引起的 IFNγ 反应(扩展数据图 6e–g)。这些结果表明,信号输出和细胞选择性不仅由受体占据情况决定,而且由受体交联的精确拓扑结构和几何形状决定。
总之,这些结构和功能研究表明,msIL-10R激动剂将IL-10Rα和IL-10Rβ组装成一种与天然IL-10家族细胞因子诱导的受体几何构型不同的构型。这种独特的四价组装为msIL-10R激动剂强大的髓系选择性信号传导特性提供了结构基础。
IL-10R拷贝数驱动选择性
我们进一步探究msIL-10R激动剂髓系选择性的分子基础。在人巨噬细胞中,msIL-10R激动剂诱导了TYK2、JAK1和STAT3磷酸化,在2 h时间点TYK2磷酸化比IL-10更持久(图4a和补充图12)。相比之下,在T细胞中,msIL-10R激动剂几乎不引起JAK1或TYK2磷酸化,并显著降低STAT3激活,免疫印迹(图4b和补充图13)和流式细胞术(图2g和补充图8)结果均证实了这一点。
a,b,单核细胞来源巨噬细胞(MDMs)(a)和T细胞(b)在指定时间点用IL-10或msIL-10R激动剂刺激,或在TYK2抑制剂存在或缺失情况下,对JAK1、TYK2和STAT3磷酸化的免疫印迹分析。展示的是来自4名供体的代表性实验。条带强度定量见补充图12和13。c,在TYK2抑制剂存在或缺失条件下,或用TYK2敲除巨噬细胞处理的人类单核细胞中,msIL-10R激动剂诱导的pSTAT3(n = 3名供体)。每个直方图旁显示MFI值。Unstim.,未刺激。d,e,经msIL-10R激动剂处理的LPS刺激人PBMCs(d)或野生型(WT)和TYK2敲除人巨噬细胞(e)上清液中的TNF浓度。n = 3名供体。f,稳定表达IL-10Rα和IL-10Rβ的野生型(WT)或TYK2-敲除HEK293T细胞中,经IL-10、泛IL-10R激动剂、msIL-10R激动剂(E07-A05/E07-A05)或A05-A05/E07-E07刺激后,STAT3荧光素酶报告基因活性。反应以重组IL-10为基准归一化,设为100%。n = 3个生物学重复。g,各免疫细胞群中IL-10Rα和IL-10Rβ的surface拷贝数。Act.,活化。n = 9名供体。h,经IL-10或msIL-10R激动剂处理、或有或无IL-10Rα和/或IL-10Rβ过表达(OE)的CD8+ T细胞中pSTAT3或granzyme B的MFI。n = 3名供体。i,全血在体外用指定激动剂处理后,各免疫细胞群中pSTAT3的MFI。n = 3名供体。j,经IL-10或msIL-10R激动剂处理的活化CD8+ T细胞中granzyme-B阳性细胞的百分比。n = 3名供体。除非另有说明,IL-10和msIL-10R激动剂使用浓度均为10 nM。数据为均值 ± 标准差(s.d.)。圆点代表单个生物学重复。统计学比较采用双尾非配对t检验(d和e)以及Dunnett多重比较检验的单因素方差分析(h和j)。
值得注意的是,msIL-10R激动剂诱导的信号传导严格依赖于TYK2。TYK2的基因敲除或药理学抑制完全消除了巨噬细胞中的STAT3磷酸化和抗炎活性(图 4a,c–e)。这一依赖性在STAT3–荧光素酶报告系统中得到进一步验证,该系统显示msIL-10R激动剂活性需要TYK2的存在(图 4f)。值得注意的是,非髓系选择性四价IL-10R激动剂,包括泛IL-10R激动剂和A05-A05/E07-E07构建体,在TYK2敲除细胞中保留了部分STAT3磷酸化(图 4f),突显了msIL-10R激动剂对TYK2的独特依赖性。同样,在来自人类IL10RA/IL10RB敲入小鼠的BMDM中,TYK2抑制消除了对TNF和IL-6的抑制,而JAK1反式磷酸化抑制剂VVD-118313的影响最小(扩展数据图 7a–d)。综上所述,这些结果表明msIL-10R激动剂施加的独特受体交联几何结构损害了有效的JAK1–JAK1反式磷酸化,使信号传导传播严格依赖于TYK2激酶活性。这一机制为其降低的信号幅度和髓系选择性提供了分子解释。
髓系细胞(单核细胞、巨噬细胞、树突状细胞)表面表达的IL-10Rα和IL-10Rβ拷贝数比T细胞、B细胞或自然杀伤(NK)细胞高2至18倍(图 4g)。为了确定受体丰度是否决定msIL-10R激动剂的选择性,我们在活化的CD8+ T细胞中异位表达IL-10Rα和/或IL-10Rβ。将IL-10Rα表达水平提高至与人类单核细胞观察到的水平相当(扩展数据图 8a),显著恢复了由msIL-10R激动剂或IL-10单体诱导的STAT3磷酸化(图 4h和扩展数据图 8b–e)。共表达IL-10Rα和IL-10Rβ进一步增强了msIL-10R激动剂相对于非过表达对照的颗粒酶B产生(图 4h和扩展数据图 8b,c)。单独过表达IL-10Rβ、TYK2或JAK1是不够的(扩展数据图 8b–i)。因此,IL-10Rα和IL-10Rβ的差异拷贝数是髓系选择性IL-10R激动作用的关键决定因素。
我们认为,如果受体丰度决定了选择性,那么将 IL-10Rα 与在淋巴细胞上富集的受体配对,应能将 STAT3 激动剂信号转导重定向至 T 细胞。IL-2Rγ(共 γ 链)在 T 细胞和 NK 细胞上的表达水平约为髓系细胞的十倍31。因此,我们生成了一组靶向 IL-10Rα 和 IL-2Rγ 的双特异性纳米抗体。两个先导结构,称为 T/NK IL-10R 激动剂,在 CD8+ T 细胞和 NK 细胞中优先诱导 STAT3 和 STAT1 而非 STAT5 磷酸化32,促进 T 细胞中颗粒酶 B 的产生,并在单核细胞中表现出极小的活性(图. 4i,j 和扩展数据图. 9a–c)。与 msIL-10R 激动剂类似,活性高度依赖于受体几何构型,因为对称的串联 VHH 拓扑在保留受体结合亲和力的同时完全消除了信号传导(扩展数据图. 9d–f)。总之,这些数据表明,细胞类型特异性的 IL-10R 激动作用由靶受体的相对丰度和配对决定,从而通过工程化的双特异性纳米抗体实现选择性。
msIL-10R 激动剂抑制炎症
IL-10 主要通过抑制细胞因子产生和 DC 成熟来限制组织炎症11,13,33。msIL-10R 激动剂完全重现了这些活性,强效阻断 GM-CSF 驱动的白细胞向 CD1a+ DCs 分化的过程(图. 5a),并抑制酵母多糖刺激的 DCs 释放 TNF 和 IL-23(图. 5b)。在抗原呈递实验中,用 msIL-10R 激动剂或 IL-10–Fc 预处理 DCs 严重损害了肽脉冲后流感 HA–四聚体+ T 细胞的扩增(图. 5c)。该激动剂还类似天然 IL-10,通过巨噬细胞中 FcγR 信号传导减轻免疫复合物触发的 TNF 产生(图. 5d)。因此,这些数据表明 msIL-10R 激动剂强效抑制 DC 分化、细胞因子分泌和 T 细胞致敏,以及巨噬细胞促炎细胞因子的产生。
a,使用GM-CSF和指定处理培养7天的人类血液单核细胞分化而来的CD1a+ DCs所占比例。左侧为代表性流式细胞术图;右侧为定量结果。n = 4位供体。b,用指定处理处理的曲霉组分(zymosan)刺激的人类DCs上清液中的TNF和IL-23浓度。n = 4位供体。c,与用HA肽脉冲处理的经指定处理预处理过的DCs共培养后,HA-四聚体+CD4+ T细胞的扩增。n = 5位供体。d,在用指定处理存在的情况下,免疫复合物刺激表达人类IL-10Rα–IL-10Rβ的RAW264.7细胞上清液中的TNF浓度。n = 3个生物学重复。e,人类IL10RA/IL10RB敲入小鼠腹腔注射(i.p.)LPS后4小时的血清TNF、IL-6和IL-12浓度。n = 5只小鼠。f–h,由KLH/铝盐诱导的迟发型超敏反应模型。f,随时间变化的耳厚度变化。n = 来自8只小鼠的16个耳部测量值。s.c.,皮下注射。g,引流淋巴结中中性粒细胞的比例。n = 8只小鼠。h,用KLH在体外重新刺激后的引流淋巴结细胞上清液中的IFNγ和TNF浓度。n = 8只小鼠。i–l,DSS诱导的结肠炎模型。i,实验方案。j,结肠重量与长度之比。k,脾脏中中性粒细胞的比例。l,结肠组织中Tnf、Il1b和Csf3r的相对表达。DSS组,n = 8只小鼠;无DSS组,n = 3只小鼠。数据为均值 ± 标准差。圆点代表单个生物学重复。统计比较使用单向方差分析(one-way ANOVA)结合Dunnett多重比较检验(超过两组)进行。
由于msIL-10R激动剂对小鼠IL-10受体缺乏交叉反应性,我们在人类IL10RA/IL10RB敲入小鼠中评估了其体内效力。在LPS攻击模型中,msIL-10R激动剂和IL-10–Fc等效地抑制了全身性TNF、IL-6和IL-12的产生34(图 5e)。在由钥匙孔巨扇贝血蓝蛋白(KLH)/铝盐诱导的迟发型超敏反应模型中,msIL-10R激动剂减少了耳部肿胀(图 5f),减少了引流淋巴结中的中性粒细胞浸润(图 5g),并减弱了KLH特异性IFNγ和TNF在体外的回忆反应(图 5h)。类似地,在葡聚糖硫酸钠(DSS)诱导的结肠炎中(图 5i),msIL-10R激动剂改善了结肠重量/长度比值(图 5j),减轻了全身性中性粒细胞扩增(图 5k),并降低了包括Tnf、Il1b和Csf3r在内的促炎基因的组织表达(图 5l)。总体而言,这些结果表明msIL-10R激动剂在多种人类化体内模型中赋予了髓系限制性抗炎活性,忠实地重现了天然IL-10的免疫调节功能。
Native IL-10 has a short serum half-life (2.7–4.5 h in humans), and long-acting variants such as PEGylated IL-10 or IL-10 Fc fusions extend exposure but drive undesirable T cell activation and haematological toxicities including anaemia/thrombocytopenia in preclinical and clinical studies2,4,6. In cynomolgus monkeys, a fully humanized version of the msIL-10R agonist exhibited dose-proportional exposure, sustained receptor occupancy on blood monocytes and a terminal half-life of approximately 8 days (Extended Data Fig. 10a,b). Ex vivo LPS challenge of whole blood from dosed animals confirmed durable suppression of TNF for more than 3 weeks after a single dose (Extended Data Fig. 10c). Importantly, whereas IL-10–Fc induced IL-18 (a reported biomarker for T cell activation and haematological toxicity in cynomolgus monkeys4,35) at 0.25 mg kg−1, and thrombocytopaenia and anaemia, the msIL-10R agonist showed no significant dose-dependent IL-18 elevation nor haematological abnormalities at doses up to 100 mg kg−1 (Extended Data Fig. 10d,e).
Thus, the msIL-10R agonist achieves prolonged myeloid-selective IL-10R agonism with an excellent safety profile, eliminating the T cell stimulation and haematotoxicity observed with IL-10–Fc.
Discussion
Here we describe a fully synthetic, myeloid-selective IL-10 receptor agonist that recapitulates the potent immunosuppressive activity of IL-10 in monocytes, macrophages and DCs while uncoupling the T cell stimulatory effects that have historically limited IL-10 therapeutics.
Our studies reveal a cell-type-specific requirement for TYK2 downstream of IL-10R signalling. Whereas myeloid cells retain anti-inflammatory responses despite TYK2 deficiency and partial attenuation of STAT3 signalling, T cells exhibit a much greater dependence on TYK2 activity and maximal pathway activation. We further demonstrate that pSTAT3 signalling strength can be finely tuned through nanobody-mediated engineering of receptor geometry, thereby enabling the development of the msIL-10R agonist. The tetravalent architecture of the msIL-10R agonist imposes a distinct mode of receptor cross-linking that renders signalling strictly TYK2 dependent and highly sensitive to receptor density. Myeloid cells express substantially higher surface levels of both IL-10Rα and IL-10Rβ, enabling efficient receptor clustering and robust downstream signalling. By contrast, lower receptor abundance on T and B cells appears insufficient to achieve the avidity threshold required for productive signalling. Although receptor abundance emerged as the determinant of selectivity, additional mechanisms may contribute. T cells may possess higher signalling thresholds or enhanced negative regulatory mechanisms, including phosphatases that attenuate IL-10R signalling36, thereby further restricting responses to attenuated IL-10R agonists. Together, these findings suggest that receptor copy number and cell-intrinsic signalling thresholds cooperate to establish the natural myeloid bias observed with attenuated IL-10R signalling and provide a mechanistic framework for engineering cell-type-selective cytokine agonists37.
Previous efforts to achieve selective IL-10 signalling primarily relied on affinity tuning through partial disruption of IL-10Rβ engagement20. Although these approaches demonstrated a proof of concept for in vitro functional selectivity, residual STAT3 signalling and T cell activation were consistently observed20 (Extended Data Fig. 3). By contrast, the msIL-10R agonist achieves improved cell type selectivity between myeloid and lymphoid populations through engineered receptor geometry rather than cytokine mutagenesis, which is constrained by the native cytokine interaction interfaces. The structural basis of receptor engagement also offers advantages in disease settings in which native IL-10 signalling is compromised. A substantial fraction of patients with very-early-onset IBD have IL10RA mutations that impair ligand–receptor interactions. As the msIL-10R agonist engages epitopes spatially distinct from the native cytokine-binding interface, signalling remained preserved across multiple pathogenic IL10RA variants examined in this study (Fig. 3h). Moreover, the fully synthetic nanobody scaffold lacks sequence homology to IL-10 and would be expected to resist neutralization by endogenous anti-IL-10 autoantibodies reported in IBD25.
In summary, we identify a cell-type-specific requirement for TYK2 in IL-10R signalling that arises from differential receptor abundance and signalling thresholds across immune cell populations. By exploiting these natural differences, we engineered a precision IL-10 therapeutic that preserves full anti-inflammatory potency while substantially reducing historical on-target liabilities. The msIL-10R agonist therefore represents a differentiated therapeutic candidate for IBD and other myeloid-driven inflammatory diseases, while the underlying engineering principles provide a generalizable blueprint for cell-type-specific cytokine agonists and antagonists across immunology and oncology.
Methods
Alpaca immunization and VHH immune phage library biopanning
Six alpacas were immunized subcutaneously with the ECD of hIL-10Rα, hIL-10Rβ or a hIL-10Rα–hIL-10Rβ heterodimer–hIgG1 Fc fusion (1 mg, five times at 2 week intervals; Lampire Biological Laboratories). All procedures were performed by Lampire under IACUC-approved protocols and applicable animal welfare regulations. No statistical methods were used to predetermine the sample size because the study was intended to isolate the antibody rather than compare groups. Animals were not randomized, and investigators were not blinded. Serum titre values were evaluated by IL-10Rα and IL-10Rβ enzyme-linked immunosorbent assay (ELISA) on days 35 and 49. Peripheral blood lymphocytes were isolated on days 49 and 63, RNA was extracted (Qiagen, 74104) and converted to cDNA, and VHH regions (~400 bp) were amplified by two-step PCR. The VHH product and pMES4 phagemid vector (Creative Biogene, OVT3038) were digested, ligated and transformed into Escherichia coli TG1 cells by electroporation; the library size was estimated by colony counting. The TG1 library was infected with M13K07 helper phage (Antibody Design lab, PH010L) to generate VHH-presenting phages, and rescue with polyethylene glycol precipitation was performed as described previously38. Phage libraries were panned against hIL-10Rα or hIL-10Rβ immobilized on MaxiSorp plates (Thermo Fisher Scientific, 439454); non-specific phage was washed away and bound phage was eluted at low pH, neutralized and used to infect TG1 cells for subsequent rounds. Enrichment was monitored by comparing eluted phage titre from antigen-coated versus uncoated wells, and stringency was increased each round by adding washes and alternating blocking reagents. Enriched phages were plated for single-colony phage ELISA.
Generation of humanized and knockout mouse lines
Double-humanized B-hIL10RA/hIL10RB mice (Biocytogen, 111871) were obtained by intercrossing B-hIL10RA and B-hIL10RB mice, both generated on a C57BL/6 background by homologous recombination. B-hIL10RA mice express a chimeric receptor in which mouse Il10ra exons 1–6 (signal peptide, ECD, transmembrane domain) were replaced with the human sequences while retaining the mouse cytoplasmic domain; B-hIL10RB mice similarly carry humanized Il10rb exons 2–6 (Supplementary Figs. 14 and 15). Tyk2-deficient mice were generated by Taconic Biosciences using CRISPR–Cas9 editing (deletion of exons 4–23) on the C57BL/6NTac background.
Protein expression and purification
Designed VHH molecules were codon-optimized, synthesized and cloned as bivalent VHH-hIgG1 with a short Gly-Ser linker. Plasmids were transiently transfected using the Expi293 or ExpiCHO systems (Thermo Fisher Scientific, A14635, A29133), and VHH-Fc constructs were purified by protein A affinity chromatography (5 ml HiTrap MabSelect-SuRe column, Cytiva, 11003495) followed by size-exclusion chromatography (SEC) (HiLoad 16/600 Superdex 200 pg column, Cytiva, 28989335); purity was assessed by analytical SEC, SDS–PAGE and mass spectrometry. The tandem VHH E07-A05, individual VHHs, anti-VHH tool Fab (Fab 1; PDB: 7PIJ) and framework-mutant variants were expressed and purified similarly. Null-binding variants were generated by introducing CDR mutations into VHH E07 or VHH A05 to abolish binding to IL-10Rα and IL-10Rβ, respectively. Human IL-10Rα and IL-10Rβ ECDs were expressed with C-terminal 8×His or hIgG1 Fc tags and purified by Ni-NTA or protein A chromatography followed by SEC. To improve cryo-EM map quality, IL-10Rα ECD was partially deglycosylated with PNGase F (37 °C, 1 h) and repurified by SEC. Complexes containing IL-10Rα ECD, IL-10Rβ ECD, tandem VHH E07-A05 and tool Fab were assembled, analysed by SEC-HPLC in 25 mM HEPES pH 7.5/150 mM NaCl. IL-10 muteins (10DE, D25K, E96K) were cloned into the PB510B mammalian expression vector (SBI System biosciences) containing an N-terminal HSA signal peptide and a C-terminal 6×His tag, and expressed in TurboCHO cells (GenScript) and purified by AmMag Ni magnetic beads (GenScript, L00776-4) followed by SEC (HiLoad 16/600 Superdex 75 pg column, Cytiva) in 25 mM HEPES pH 7.4/150 mM NaCl. Detailed protein and antibody sequence information is provided in the Supplementary Table 4.
Human PBMC stimulation
PBMCs from healthy donors were stimulated with 10 ng ml−1 LPS in the presence of PBS, recombinant human IL-10 (Peprotech, 200-10) or msIL-10R agonist (0.005–1,000 nM). For TYK2 inhibitor experiments, cells were pretreated with DMSO or zasocitinib (MedChemExpress, HY-150096, 1 μM) before stimulation. After 24 h, supernatant TNF, IL-6 and IL-1β were measured using the Meso Scale Discovery (MSD, K15049D) assay and analysed in GraphPad Prism.
MDM differentiation and CRISPR editing
Monocytes were isolated from PBMCs by negative selection (StemCell Technologies, 19359) and differentiated into MDMs in M-CSF–supplemented RPMI for at least 6 days. For TYK2 knockout, freshly isolated monocytes were nucleofected with Cas9–guide RNA ribonucleoprotein (RNP) complexes (Lonza 4D Nucleofector) and differentiated for 6 days before downstream phosphoflow or cytokine assays. RNPs were generated by combining 2 μl gRNA (100 μM) and 2 μl of Cas9 (20 μM) (EditCo) in supplemented P3 nucleofection buffer (Lonza, V4SP-3096). The solution was incubated at room temperature for 20 min. In total, 106 monocytes were resuspended in 20 μl of pre-formed RNPs in P3 buffer and nucleofected using Lonza 4D Nucleofector using pulse code CM-137.
T cell isolation and in vitro T cell assay
Human bulk or CD8+ T cells were isolated from PBMCs by negative selection (>99% purity, StemCell Technologies, 17951, 17953) and activated with plate-bound 10 μg ml−1 anti-CD3 and soluble 5 μg ml−1 anti-CD28 for 3 days. T cells were then cultured with or without IL-10, msIL-10R agonist, IL-10 monomer or IL-10 muteins for 3 additional days, restimulated with anti-CD3/anti-CD28 (5 μg ml−1 each) overnight and assessed for secreted IFNγ and granzyme B by ELISA and MSD (R&D, DIF50C, DGZB00; MSD, K251TTK) or by intracellular flow cytometry.
CRISPR–Cas9 gene editing in T cells and HEK293T cells
Activated human T or CD8+ T cells were nucleofected with Cas9–gRNA RNP complexes and poly-l-glutamic acid using a 4D Nucleofector (Lonza) and expanded for 3 days before use. RNP complexes were generated by incubating guide RNA (EditCo Bio) with recombinant Cas9 protein (IDT, 10007803) for 20 min at room temperature. Cells were electroporated using the EO115 pulse program. To generate TYK2-knockout HEK293T IL-10 pSTAT3 reporter cells, Cas9–RNP complexes targeting TYK2 were assembled using a predesigned human TYK2 gene knockout kit (EditCo) and delivered by electroporation using the Neon Transfection System (Thermo Fisher Scientific). After recovery, single-cell clones were isolated by flow cytometry single-cell sorting and expanded. TYK2 knockout was confirmed by DNA-seq.
Lentiviral transduction
Human CD8+ T cells were activated with anti-CD3/anti-CD28 Dynabeads overnight, debeaded and transduced with concentrated lentivirus encoding IL10RA-mCherry, IL10RB-GFP, JAK1-GFP or TYK2-mCherry (cloned into the GLV3 backbone under the EF1A promoter with C-terminal P2A-mCherry/EGFP reporters) by spin-infection on retronectin-coated plates (100 μg ml−1, Takara, T100B). Cells were rested 2–3 days before functional assays. The gating strategy for transduced T cells is shown in Supplementary Fig. 16.
pSTAT3 and pSTAT1 staining
After stimulation, PBMCs, MDMs or T cells were surface stained, fixed, permeabilized with ice-cold methanol and stained with anti-pSTAT3 (pY705) and anti-pSTAT1 (pY701). Cells were analysed by flow cytometry (LSR Fortessa) and quantified in FlowJo. The gating strategy is shown in Supplementary Fig. 17.
Copy numbers of IL-10Rα and IL-10Rβ
PBMCs, macrophages (detached from UpCell plates with cold PBS) and monocyte-derived DCs (CellXVivo, CDK004) were stained with lineage markers and titrated anti-IL-10Rα and anti-IL-10Rβ antibodies with matched isotype controls. The delta geometric mean fluorescence intensity (gMFI) was calculated as the sample gMFI minus the isotype gMFI. Absolute receptor copy numbers were determined using Quantum Simply Cellular anti-rat and anti-mouse IgG bead standards (Bangs Laboratories, 817B, 815B). Antibody details are provided in the Reporting Summary.
Immunoblot analyses
Macrophages or T cells were serum-starved, pretreated with DMSO, JAK1 inhibitor upadacitinib (10 µM) or TYK2 inhibitor zasocitinib (1 µM), and stimulated with or without IL-10 or msIL-10R agonist (10 nM). The lysates were resolved on NuPAGE 4–12% Bis-Tris gels, transferred to nitrocellulose and probed for phosphorylated and total TYK2, JAK1, STAT3, STAT1 and GAPDH. Chemiluminescence was detected on the ChemiDoc MP system and quantified in Image Lab, with brightness/contrast adjustments applied uniformly across all groups. pTYK2, pJAK1 and pSTAT3 were normalized to total TYK2 and expressed as the fold change relative to the unstimulated control. Antibody details are provided in the Reporting Summary.
IL-10Rα–IL-10Rβ pSTAT3 reporter assay
An HEK293T reporter line stably expressing human IL10RA, IL10RB and a STAT3-responsive firefly luciferase reporter was used to measure IL-10 receptor agonist activity. Reporter cells were incubated with eight-point dose–responses of test molecules or recombinant IL-10 (positive control) for 3 h, and luminescence was measured using an EnVision reader (Revvity) after Bio-Glo addition (Promega, G7941). The half-maximum effective concentration and Emax were calculated by four-parameter logistic regression on the IL-10-normalized signal.
Inhibition of LPS-mediated PBMC cytokine secretion
Thawed PBMCs were pre-incubated with eight-point dose–responses of IL-10 or antibodies for 30 min, stimulated with LPS (1 ng ml−1) for 20 h, and supernatant IL-6 and TNF were measured by time-resolved Förster resonance energy transfer (Revvity, TRF1223C) and MSD (K151UCK), respectively. Data were normalized to positive/negative controls and fitted by four-parameter logistic regression.
Evaluation of the IL-10R agonist activity on primary T cells
CD8+ T cells from three donors were expanded for 3 days with anti-CD3/anti-CD28, incubated with eight-point antibody dose–responses for 3 days, restimulated with anti-CD3/anti-CD28 for 6 h and the supernatant IFNγ was measured by MSD (K151TTK). Data were normalized and fitted by four-parameter logistic regression.
RAW264.7 knockout and IL10RA-mutant cell line generation
Endogenous Il10ra and Il10rb were disrupted in RAW264.7 cells by CRISPR–Cas9 nucleofection using a Lonza 4D Nucleofector with pulse code DS-136, and single-cell knockout clones were validated by genomic sequencing and flow cytometry. IL-10R-deficient cells were then reconstituted by lentiviral expression of chimeric receptors (human IL-10Rα/IL-10Rβ ECDs fused to the corresponding mouse intracellular domains, linked by P2A), including IBD-associated IL-10Rα extracellular mutants. To assess anti-inflammatory activity, cells were stimulated with LPS (10 ng ml−1) with or without IL-10, IL-10 muteins (10DE, D25K) or msIL-10R agonist (0.1–10 nM) for 6 h with monensin, and intracellular TNF was measured by flow cytometry. For immune complex assays, RAW264.7 cells expressing human IL-10Rα and IL-10Rβ were cultured with mouse IgG2a antibody (10 μg ml−1) and 10 nM isotype control, IL-10 Fc, or msIL-10R agonist for 1 h before addition of 10 μl Dynabeads Protein A to generate immune complexes. After 24 h, culture supernatants were harvested and cytokines quantified by MSD.
SPR measurement of binding kinetics
Antibody binding to human and cynomolgus macaque (cyno) IL-10Rα and IL-10Rβ was measured on the Biacore 8K system. The C1 chip (Cytiva VR100535) was preconditioned with glycine-NaOH/Triton X-100, activated with s-NHS/EDC chemistry, and anti-human Fc (Southern Biotech, 2014-1) was amine-coupled in sodium acetate (pH 5.0) to a final density of around 500 RU for antibody capture through the Fc tag; excess activated carboxyls were quenched with ethanolamine. Antibodies were captured at 50 nM to around 50–60 RU per channel. After ten blank buffer injections for stabilization, human and cyno IL-10Rα were injected as a threefold concentration series (150 nM top) and IL-10Rβ as a threefold series (1,000 nM top), using 180 s association and 30 min dissociation at 25 °C in 10 mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.005% Tween-20 and 0.2 mg ml−1 BSA, with 10 mM glycine (pH 1.5) regeneration between cycles. Data were fit to a simple 1:1 kinetic model to derive kon and koff, from which KD was calculated (KD = koff/kon).
Cryo-EM sample preparation and data acquisition
To facilitate cryo-EM study of the IL-10Rα–IL-10Rβ–tandem VHH E07-A05 complex, framework mutations (Lys116/Pro119/Lys244/Pro247) were introduced into the tandem VHH so that a tool anti-VHH Fab (Fab 1; PDB: 7PIJ) could bind to and enlarge the particle. When IL-10Rα ECD, IL-10Rβ ECD, tandem VHH and tool Fab 1 were mixed at a 1:1:1:2 molar ratio (0.8 mg ml−1, in 25 mM HEPES pH 7.5 and 150 mM NaCl), the Fab bound preferentially to the engineered site on A05 but heterogeneously to E07, of which the engineered Fab site is not solvent exposed in the complex (Extended Data Fig. 4). To improve homogeneity, IL-10Rα ECD, IL-10Rβ ECD and tandem VHH were pre-incubated on ice for 1 h before adding tool Fab 1 to a 1.2:1:1:1 final molar ratio, which markedly improved particle homogeneity in 2D and 3D classification (Supplementary Fig. 10). For the IL-10Rα–VHH E07 complex, partially deglycosylated IL-10Rα ECD, VHH E07 and a second anti-VHH Fab (Fab 2, GenScript, A02165) were mixed at a 1.2:1:1 molar ratio (1.3 mg ml−1, in 25 mM HEPES pH 7.5 and 150 mM NaCl) and incubated on ice for 1 h. Deglycosylation significantly improved IL-10Rα density in the map. Complexes were cross-linked with 0.05% glutaraldehyde (15 min on ice in the dark), and a 3.5 µl aliquot was applied to a glow-discharged UltrAuFoil R1.2/1.3 grid (R1.2/1.3, Quantifoil), blotted in Vitrobot Mark IV (Thermo Fisher Scientific) (2 s, 4 °C, 100% humidity), and plunge-frozen in liquid ethane. Both untilted and stage-tilted (15–30°) data were acquired to improve angular sampling. Videos were collected in EPU (Thermo Fisher Scientific) on the Titan Krios system (300 kV) (Thermo Fisher Scientific) with a Falcon 4i direct electron detector (Thermo Fisher Scientific) at ×165,000 nominal magnification (0.729 Å per pixel), a defocus range of −0.6 to −2.2 µm, and a Selectris X energy filter (10 eV slit), over a 5.85 s exposure with 50 frames and a total dose of around 50 e− Å−2.
Cryo-EM image processing and model building
All data processing was performed in CryoSPARC (v.4)39 with patch motion correction and patch contrast transfer function (CTF) estimation; images with CTF fit to 5.5 Å or better were retained. For the IL-10Rα–IL-10Rβ–tandem VHH E07-A05–anti-VHH Fab complex (Supplementary Fig. 10), 15,755 untilted videos (two sessions of 6,460 and 9,295) and 7,508 tilted (15–30°) videos were collected, processed separately and merged after 2D classification, yielding 2,730,139 particles used for iterative heterogeneous refinement, 3D classification and non-uniform refinement with local and global CTF refinement to give a 3.14 Å map (FSC = 0.143; 101,358 particles). For the IL-10Rα–VHH E07–anti-VHH Fab complex (Supplementary Fig. 11), 19,416 untilted videos (two sessions of 9,680 and 9,736) and 7,461 tilted (15–30°) videos yielded 1,215,819 particles used for ab initio reconstruction, heterogeneous refinement and non-uniform refinement with local and global CTF refinement, giving a 2.40 Å map (FSC = 0.143; 458,458 particles). The IL-10Rα structure (PDB: 1Y6K) and an AlphaFold40 model of VHH E07 were docked into the 2.40 Å map by rigid-body fitting in ChimeraX41, manually adjusted in Coot42 and refined with phenix.real_space_refine43. The refined IL-10Rα–VHH E07 model, together with IL-10Rβ (PDB 3LQM) and the anti-VHH tool Fab (PDB 7PIJ), served as initial models to refine against the 3.14 Å complex map. The Gly-Gly-Gly-Ser inter-VHH linker was not resolved and was omitted from model building. Structural figures were generated and validated using standard cryo-EM refinement metrics, with full processing pipelines, particle counts and map–model statistics provided in Supplementary Figs. 10 and 11 and Supplementary Table 5.
DSS-induced colitis model
Ten-week-old female humanized IL10RA/IL10RB mice received 2% DSS in drinking water for 7 days and were dosed three times weekly with isotype control, IL-10 Fc or msIL-10R agonist (1 nmol per mouse). Colon length and weight were measured on day 10 and colonic gene expression was quantified by TaqMan qPCR. Neutrophil gating is shown in Supplementary Fig. 18.
LPS-induced sepsis model
Six-week-old female humanized IL10RA/IL10RB mice received intraperitoneal LPS (E. coli O111:B4, 4 mg kg−1) with a single dose of isotype control, human IL-10 Fc or msIL-10R agonist. Serum TNF, IL-6 and IL-12p70 were measured 4 h later by MSD (N05048A-1).
KLH-induced DTH sensitization recall model
Humanized IL10RA/IL10RB mice were sensitized subcutaneously with KLH/complete Freund’s adjuvant (Sigma, H7017; Chondrex, 7009), dosed intraperitoneally on day 4 with isotype, IL-10 Fc or msIL-10R agonist (2 mg kg−1), rechallenged intradermally with KLH in the ear on day 5, and taken down on day 8. Draining lymph node cells were restimulated ex vivo with KLH, and supernatant cytokines were measured by MSD (N05048A-1).
RNA extraction, library generation and sequencing for RNA-seq analysis
Total RNA was extracted (Qiagen, 74104), quality-checked and used (500 ng) for TruSeq stranded mRNA library preparation and paired-end sequencing on an Illumina NextSeq2000. A Nextflow pipeline performed quality control (FastQC, RNA-SeQC2, MultiQC), alignment to GRCh38 with STAR and gene quantification with featureCounts44,45. Differential expression used TMM normalization and edgeR (glmQLFit/glmQLFTest) with Benjamini–Hochberg FDR < 0.05.
DC differentiation and cytokine secretion
CD14+ monocytes were differentiated into DCs with IL-4 and GM-CSF for 6 days, with IL-10 Fc or msIL-10R agonist (10 nM) present throughout differentiation, and CD1a/CD14 expression was assessed by flow cytometry. The gating strategy is shown in Supplementary Fig. 17. For activation, DCs were stimulated with zymosan with or without IL-10–Fc or msIL-10R agonist molecules for 24 h, and TNF and IL-23 were measured by MSD.
DC antigen presentation to HA-specific CD4+ T cells
Monocyte-derived DCs were differentiated (R&D Systems, CDK004) and matured (IL-4, GM-CSF, TNF and LPS) in the presence of isotype control, IL-10 Fc or msIL-10R agonist (1 or 10 nM), then pulsed with influenza haemagglutinin HA307 peptide (Influenza A HA 307–319, DRA1*01:01/DRB1*04:01, PKYVKQNTLKLAT). HA307-reactive CD4+ T cells from an HLA-DRB1*04:01 donor were expanded, tetramer-sorted and co-cultured with peptide-pulsed DCs. Expansion of tetramer+ T cells was assessed by flow cytometry using the gating strategy shown in Supplementary Fig. 18.
Pharmacokinetic assessment in cynomolgus monkey
Plasma concentrations of msIL-10R agonist and IL-10 Fc were measured by an MSD electrochemiluminescence assay using anti-human Fc capture (Southern Biotech, 9048-08) and SULFO-TAG anti–IL-10Rα detection, with a lower limit of quantification of 15 ng ml−1 and concentrations back-calculated from four-parameter logistic standard curves.
In vitro human B cell activation and plasmablast differentiation
Isolated human B cells (StemCell Technologies, 17954) were cultured with recombinant CD40 ligand (R&D, 6420-CLB, 1 μg ml−1) and IL-10 (10 nM), fed on day 3, and collected on day 6. Plasmablasts (CD19+CD27+CD38+) were quantified by flow cytometry, and the gating strategy is shown in Supplementary Fig. 19.
BMDM differentiation, pSTAT3 signalling and cytokine-secretion assays
Bone marrow from wild-type or Tyk2-deficient mice was differentiated into BMDMs with M-CSF (Gibco 31502250UG) for 5–6 days. For pSTAT3 induction, BMDMs were pretreated with upadacitinib (Tocris, 7783, 10 µM) or the JAK1-selective inhibitor VVD-118313 (MedChemExpress, HY-151385, 100 nM) and stimulated with IL-10–Fc (10 nM); intracellular pSTAT3 was measured by flow cytometry. For cytokine secretion, BMDMs were pretreated with upadacitinib, VVD-118313 or zasocitinib (1 µM), stimulated with IL-10 Fc and LPS, and supernatant cytokines were measured by MSD.
Statistical analysis
All analyses were performed using two-tailed Student’s t-tests, log-normalized Welch’s t-tests or one-way/two-way ANOVA with correction for multiple comparisons (GraphPad Prism 8). All bar graphs show means with overlaid scatter and s.d. as indicated in each figure legend.
Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.
Data availability
Human PBMC and T cell RNA-seq data are available under NCBI GEO accessions GSE318914 (PBMCs) and GSE318915 (T cells). Cryo-EM density maps are deposited under EMD-75301 (IL-10Rα–VHH E07–anti-VHH Fab) and EMD-75302 (IL-10Rα–IL-10Rβ–tandem VHHs E07-A05–anti-VHH Fab); model coordinates are deposited under PDB 10ND and 10NE. Uncropped gels and blots are provided in Supplementary Fig. 1. Source data are provided with this paper.
References
Ouyang, W. & O’Garra, A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 50, 871–891 https://doi.org/10.1016/j.immuni.2019.03.020 (2019).
Cardoso, A. et al. Interleukin-10 induces interferon-γ-dependent emergency myelopoiesis. Cell Rep. 37, 109887 https://doi.org/10.1016/j.celrep.2021.109887 (2021).
Huhn, R. D. et al. Effects of single intravenous doses of recombinant human interleukin-10 on subsets of circulating leukocytes in humans. Immunopharmacology 41, 109–117 https://doi.org/10.1016/s0162-3109(98)00058-7 (1999).
Yang, Z. et al. Application of pharmacokinetic/pharmacodynamic modeling to bridge mouse antitumor efficacy and monkey toxicology data for determining the therapeutic index of an interleukin-10 Fc fusion protein. Front. Pharmacol. 13, 829063 https://doi.org/10.3389/fphar.2022.829063 (2022).
Tilg, H. et al. Treatment of Crohn’s disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut 50, 191–195 https://doi.org/10.1136/gut.50.2.191 (2002).
Saraiva, M., Vieira, P. & O’Garra, A. Biology and therapeutic potential of interleukin-10. J. Exp. Med. 217, e20190418 https://doi.org/10.1084/jem.20190418 (2020).
Glocker, E. O. et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N. Engl. J. Med. 361, 2033–2045 https://doi.org/10.1056/NEJMoa0907206 (2009).
Weber-Nordt, R. M. et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J. Biol. Chem. 271, 27954–27961 https://doi.org/10.1074/jbc.271.44.27954 (1996).
Riley, J. K., Takeda, K., Akira, S. & Schreiber, R. D. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274, 16513–16521 https://doi.org/10.1074/jbc.274.23.16513 (1999).
Takeda, K. et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10, 39–49 https://doi.org/10.1016/s1074-7613(00)80005-9 (1999).
Fiorentino, D. F. et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J. Immunol. 146, 3444–3451 (1991).
Li, B. et al. IL-10 engages macrophages to shift Th17 cytokine dependency and pathogenicity during T-cell-mediated colitis. Nat. Commun. 6, 6131 https://doi.org/10.1038/ncomms7131 (2015).
Zigmond, E. et al. Macrophage-restricted interleukin-10 receptor deficiency, but not IL-10 deficiency, causes severe spontaneous colitis. Immunity 40, 720–733 https://doi.org/10.1016/j.immuni.2014.03.012 (2014).
Saxena, A. et al. Interleukin-10 paradox: a potent immunoregulatory cytokine that has been difficult to harness for immunotherapy. Cytokine 74, 27–34 https://doi.org/10.1016/j.cyto.2014.10.031 (2015).
Tilg, H., Ulmer, H., Kaser, A. & Weiss, G. Role of IL-10 for induction of anemia during inflammation. J. Immunol. 169, 2204–2209 https://doi.org/10.4049/jimmunol.169.4.2204 (2002).
Naing, A. et al. PEGylated IL-10 (pegilodecakin) induces systemic immune activation, CD8+T cell invigoration and polyclonal T cell expansion in cancer patients. Cancer Cell 34, 775–791 https://doi.org/10.1016/j.ccell.2018.10.007 (2018).
Naing, A. et al. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncol. 20, 1544–1555 https://doi.org/10.1016/S1470-2045(19)30514-5 (2019).
Salkeni, M. A. & Naing, A. Interleukin-10 in cancer immunotherapy: from bench to bedside. Trends Cancer 9, 716–725 https://doi.org/10.1016/j.trecan.2023.05.003 (2023).
Josephson, K. et al. Design and analysis of an engineered human interleukin-10 monomer. J. Biol. Chem. 275, 13552–13557 https://doi.org/10.1074/jbc.275.18.13552 (2000).
Saxton, R. A. et al. Structure-based decoupling of the pro- and anti-inflammatory functions of interleukin-10. Science 371, eabc8433 https://doi.org/10.1126/science.abc8433 (2021).
Caveney, N. A. et al. Structural basis of Janus kinase trans-activation. Cell Rep. 42, 112201 https://doi.org/10.1016/j.celrep.2023.112201 (2023).
Kavanagh, M. E. et al. Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine. Nat. Chem. Biol. 18, 1388–1398 https://doi.org/10.1038/s41589-022-01098-0 (2022).
Josephson, K., Logsdon, N. J. & Walter, M. R. Crystal structure of the IL-10/IL-10R1 complex reveals a shared receptor binding site. Immunity 15, 35–46 https://doi.org/10.1016/s1074-7613(01)00169-8 (2001).
Shimoda, K. et al. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity 13, 561–571 https://doi.org/10.1016/s1074-7613(00)00055-8 (2000).
Griffin, H. et al. Neutralizing autoantibodies against interleukin-10 in inflammatory bowel disease. N. Engl. J. Med. 391, 434–441 https://doi.org/10.1056/NEJMoa2312302 (2024).
Chan, A. C., Martyn, G. D. & Carter, P. J. Fifty years of monoclonals: the past, present and future of antibody therapeutics. Nat. Rev. Immunol. 25, 745–765 https://doi.org/10.1038/s41577-025-01207-9 (2025).
Bloch, J. S. et al. Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins. Proc. Natl Acad. Sci. USA 118, e2115435118 https://doi.org/10.1073/pnas.2115435118 (2021).
Mendoza, J. L. et al. The IFN-λ-IFN-λR1-IL-10Rβ complex reveals structural features underlying type III IFN functional plasticity. Immunity 46, 379–392 https://doi.org/10.1016/j.immuni.2017.02.017 (2017).
Saxton, R. A. et al. The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design. Immunity 54, 660–672 https://doi.org/10.1016/j.immuni.2021.03.008 (2021).
Aschenbrenner, D. et al. Pathogenic interleukin-10 receptor alpha variants in humans—balancing natural selection and clinical implications. J. Clin. Immunol. 43, 495–511 https://doi.org/10.1007/s10875-022-01366-7 (2023).
Leonard, W. J., Lin, J. X. & O’Shea, J. J. The γc family of cytokines: basic biology to therapeutic ramifications. Immunity 50, 832–850 https://doi.org/10.1016/j.immuni.2019.03.028 (2019).
Cai, G., Kastelein, R. A. & Hunter, C. A. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-γ when combined with IL-18. Eur. J. Immunol. 29, 2658–2665 (1999).
Fiorentino, D. F., Zlotnik, A., Mosmann, T. R., Howard, M. & O’Garra, A. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147, 3815–3822 (1991).
Berg, D. J. et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J. Clin. Invest. 96, 2339–2347 https://doi.org/10.1172/JCI118290 (1995).
Iwai, Y. et al. An IFN-γ-IL-18 signaling loop accelerates memory CD8+ T cell proliferation. PLoS ONE 3, e2404 https://doi.org/10.1371/journal.pone.0002404 (2008).
Zhao, Y. et al. Expanding the cytokine receptor alphabet reprograms T cells into diverse states. Nature 645, 1039–1050 https://doi.org/10.1038/s41586-025-09393-1 (2025).
Yen, M. et al. Facile discovery of surrogate cytokine agonists. Cell 185, 1414–1430 https://doi.org/10.1016/j.cell.2022.02.025 (2022).
Hust, M. & Lim, T. S. Phage Display: Methods and Protocols 2nd edn (Humana Press, 2023).
Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290–296 https://doi.org/10.1038/nmeth.4169 (2017).
Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 https://doi.org/10.1038/s41586-021-03819-2 (2021).
Pettersen, E. F. et al. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612 https://doi.org/10.1002/jcc.20084 (2004).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 https://doi.org/10.1107/S0907444910007493 (2010).
Afonine, P. V. et al. Real-space refinement in PHENIX for cryo-EM and crystallography. Acta Crystallogr. D 74, 531–544 https://doi.org/10.1107/S2059798318006551 (2018).
Di Tommaso, P. et al. Nextflow enables reproducible computational workflows. Nat. Biotechnol. 35, 316–319 https://doi.org/10.1038/nbt.3820 (2017).
Graubert, A., Aguet, F., Ravi, A., Ardlie, K. G. & Getz, G. RNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts. Bioinformatics 37, 3048–3050 https://doi.org/10.1093/bioinformatics/btab135 (2021).
Acknowledgements
We thank W. Ouyang for providing scientific guidance throughout the project and reading the manuscript; and the staff at the Gilead core facilities, including the Sequencing Core, Protein Production Core, DST large molecule core, Flow Cytometry Core and Cryo-EM core, for their technical support.
Funding
This study is fully sponsored by Gilead Sciences.
Author information
Author notes
These authors contributed equally: D. Alejandro Canaria, Trang T. T. Nguyen, Huang Huang, Hui Xu, Lili Yue
Authors and Affiliations
Postdoctoral Program, Gilead Sciences, Foster City, CA, USA
D. Alejandro Canaria, Cong Xing & Tangsheng Yi
Inflammation Research, Gilead Sciences, Foster City, CA, USA
D. Alejandro Canaria, Trang T. T. Nguyen, Huang Huang, Lili Yue, Yongyao Fu, Cong Xing, Aron L. Martin, Zhiyu Huang, Meagan C. Main, Amanali Rodriguez, Xiaoli Lin, Maria L. Mouchess & Tangsheng Yi
Structural Biology & Chemistry, Gilead Sciences, Foster City, CA, USA
Hui Xu
Discovery Sciences & Technologies, Gilead Sciences, Foster City, CA, USA
Hoa Truong, Kerul Patel & Chen Chen
Protein Therapeutics, Gilead Sciences, Foster City, CA, USA
Weimei Xing, George Delidakis, Sylvia Wong, Andrew Pae, Yu Yu, Ramsay Macdonald, Magdeleine Hung, Lei Chen, Nicole Schirle Oakdale & Chingwei V. Lee
Research Data Science, Gilead Sciences, Foster City, CA, USA
Jayamary Divya Ravichandar
Non-Clinical Safety, Gilead Sciences, Foster City, CA, USA
Ellen M. McGlinchey
Drug Metabolism, Gilead Sciences, Foster City, CA, USA
Brian Carr & Megan L. Koleske
Authors
- D. Alejandro Canaria
- Trang T. T. Nguyen
- Huang Huang
- Hui Xu
- Lili Yue
- Yongyao Fu
- Hoa Truong
- Kerul Patel
- Weimei Xing
- Jayamary Divya Ravichandar
- Cong Xing
- Aron L. Martin
- George Delidakis
- Sylvia Wong
- Andrew Pae
- Yu Yu
- Ramsay Macdonald
- Zhiyu Huang
- Meagan C. Main
- Amanali Rodriguez
- Xiaoli Lin
- Maria L. Mouchess
- Magdeleine Hung
- Ellen M. McGlinchey
- Lei Chen
- Nicole Schirle Oakdale
- Brian Carr
- Megan L. Koleske
- Chingwei V. Lee
- Chen Chen
- Tangsheng Yi
Contributions
H.H., C.V.L., C.C. and T.Y. conceptualized the idea and initiated the project. D.A.C., T.T.T.N., H.H., L.Y., C.X., A.L.M., Y.F., H.T., K.P., C.C. and T.Y. designed, performed and analysed the in vitro biology and biochemical experiments. H.T., K.P. and C.C. performed the screening and identification of antibodies. G.D., S.W., A.P., L.C., N.S.O. and C.V.L. performed antibody engineering and humanization. Y.Y., R.M., M.H. and W.X. performed protein purification. H.X. performed the cryo-EM experiment and structural analysis. Z.H., M.C.M., A.R., X.L., M.L.M. and T.Y. designed and performed in vivo experiments. E.M.M., B.C., L.Y., T.Y. and M.L.K. designed and performed analysis of non-human primate pharmacokinetic- and clinical-pharmacology-related experiments. H.H. and J.D.R. performed and analysed RNA-seq data. All of the authors approved and contributed to the editing and revision of the manuscript.
Corresponding authors
Correspondence to Chingwei V. Lee, Chen Chen or Tangsheng Yi.
Ethics declarations
Competing interests
All of the authors are current or former employees of Gilead Sciences and may hold stock or stock options in the company. C.C., L.C., G.D., H.H., M.L.K., C.V.L., N.S.O., H.X., T.Y. and L.Y. are listed as inventors on published patent WO2026112287 (Single immunoglobulin domain bispecific antibodies against IL-10R alpha and beta subunits and methods of use).
Peer review
Peer review information
Nature thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Fig. 1 Distinct JAK1 and TYK2 requirements for IL-10 and engineered IL-10 monomer signalling.
a, Representative flow cytometry histograms of phospho-STAT3 (pSTAT3) staining in human monocyte-derived macrophages following CRISPR/Cas9-mediated knockout of the indicated genes and stimulated with 10 nM IL-10 for 15 min. NTC, non-targeting control. b, TNFα and IL-6 concentrations in supernatants from CRISPR/Cas9-edited human monocyte-derived macrophages targeting the indicated genes and stimulated with LPS plus 10 nM IL-10 for 24 h. Each dot represents an individual donor. One-way ANOVA with Dunnett’s multiple comparison test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. c, Representative flow cytometry histograms of pSTAT3 in wild-type (WT) or TYK2 deficient bone marrow derived macrophages (BMDMs) left untreated (PBS) or treated with IL-10 Fc alone or together with DMSO, JAK1 transphosphorylation inhibitor VVD-118313 (VVD), or JAK1 kinase inhibitor Upadacitinib (Upa). Mean fluorescence intensity (MFI) values are shown as mean ± standard deviation (s.d.) (n = 3 biological replicates). d, IL-6 concentrations in supernatants from LPS-stimulated BMDMs treated with IL-10 Fc in the presence of DMSO, VVD, or Upa (n = 5 or 6 biological replicates pooled from two experiments). e, Immunoblot analysis of pSTAT3, STAT3, and GAPDH in WT or TYK2 knockout mouse BMDMs stimulated with 10 nM IL-10 in the presence or absence of DMSO, Upa, or VVD (n = 3 independent immunoblots). f,g, Immunoblot analysis of phosphorylated and total JAK1, TYK2, STAT3, and STAT1 in monocyte-derived macrophages (f) and T cells (g) stimulated with 10 nM IL-10 or IL-10 monomer in the presence or absence of TYK2 inhibitor (n = 2-5 independent immunoblots). Data are mean ± standard deviation (s.d.); Dots represent individual biological replicates. Statistical comparisons were performed using one-way ANOVA with Dunnett’s multiple comparisons test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant.
Extended Data Fig. 2 Characterization of zasocitinib for IFN-α and IL-23 inhibition and TYK2 dependency of IL-10 and engineered IL-10 monomer signalling.
a, Percentage inhibition of pSTAT3 MFI by titrated TYK2 inhibitor following stimulation with the indicated STAT3-inducing cytokines in monocytes or T cells (n = 2 donors). b, pSTAT3 MFI in human monocyte-derived macrophages following CRISPR-mediated knockout of TYK2 or a non-targeting control (NTC) and stimulation with IL-10 (n = 3 donors). c, TNFα and IL-6 concentrations in supernatants from TYK2 knockout or control human macrophages stimulated with LPS alone or LPS plus IL-10 (n = 3 donors). d, Representative flow cytometry histograms of pSTAT3 in human monocytes or T cells stimulated with IL-10 in the presence of DMSO or TYK2 inhibitor (1 μM). e,f, Representative flow cytometry histograms (e) and quantification of pSTAT3 MFI (f) in non-targeting control (NTC) or TYK2 knockout macrophages following stimulation with IL-10 monomer (n = 3 donors). g, TNFα and IL-6 in supernatants from human macrophages stimulated with LPS alone or LPS plus IL-10 monomer in the presence of DMSO or TYK2 inhibitor (1 μM) (n = 3 donors). h, Quantification of TNFα and IL-6 in supernatants from LPS-stimulated PBMCs treated with titrated concentrations of IL-10 or IL-10 monomer in the presence of DMSO or the TYK2 inhibitor (1 μM) (n = 3 donors). Data are mean ± standard deviation (s.d.); dots represent biological replicates. Statistical comparisons were performed using two-tailed unpaired t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Extended Data Fig. 3 msIL-10R agonist exhibits greater T- and B-cell selectivity than affinity detuned IL-10 muteins.
a, Flow cytometric quantification of pSTAT3 MFI in human whole blood stimulated with titrated concentrations of IL-10, the msIL-10R agonist, or the indicated IL-10 muteins. Bars represent mean ± s.d. (n = 4 donors). b, Representative flow cytometry histograms of pSTAT3 staining following stimulation with the indicated molecules at 12 nM. pSTAT3-positive gates were defined using the PBS control, and the percentage of pSTAT3-positive cells is indicated. c, IFN-γ concentrations in supernatants from activated CD8+ T cells stimulated with anti-CD3/CD28 and treated with IL-10, the msIL-10R agonist, or the IL-10 muteins 10DE and D25K at 100, 20, or 4 nM for 2 days; IFN-γ concentrations were normalized within each donor to the response induced by 100 nM IL-10, which was set to 100% (n = 12 donors). d, Total B cell counts (left) and frequencies of CD38+CD27+ plasmablasts (right) in purified B cells stimulated with CD40L in the presence of the indicated molecules at 10 nM (n = 4 donors). Data are mean ± standard deviation (s.d.); dots represent biological replicates. Statistical comparisons were performed using one-way ANOVA with Dunnett’s multiple-comparison test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
Extended Data Fig. 4 Cryo-EM protein construct design and sample optimization.
a, Protein sequence alignment of tandem VHHs E07-A05 and VHH E07 used for cryo-EM studies, generated with Clustal Omega1. Residues at Fab interface resolved in the structures are indicated by coloured dots (green: A05-Tool Fab #1, brown: E07-Tool Fab #2). Yellow dots denote the predicted tool Fab #1 binding site in E07, which is not solvent-exposed in the pre-formed IL-10Rα:IL-10Rβ:tandem VHHs E07-A05 complex. b, Cryo-EM structure of the IL-10Rα:IL-10Rβ:tandem VHHs E07-A05:anti-VHH Fab #1 complex, with a close-up view of VHH E07:A05:Fab interface. A05 residues interacting with Fab #1, including engineered binding site mutations K244/P247, are highlighted as green sticks. Predicted Fab #1 binding residues in E07, including engineered binding site mutations K116/P119, are highlighted as yellow sticks and are inaccessible to a second Fab molecule in the pre-formed IL-10Rα:IL-10Rβ:tandem VHHs E07-A05 complex. c, Representative cryo-EM 2D class averages of the IL-10Rα:IL-10Rβ:tandem VHHs E07-A05:anti-VHH Fab #1 complex prepared at 1:1:1:2 molar ratio. d, Two cryo-EM maps obtained after 3D classification reveal heterogeneity in the orientation of E07 relative to A05, likely resulting from binding of a second Fab molecule to E07. e, Modelling of a second Fab bound to E07 (yellow circle) indicates steric clash with VHH A05.
Extended Data Fig. 5 Structural comparison of IL-10Rβ in complex with VHH A05 or IL-10 family cytokines.
Structures of IL-10Rα:IL-10Rβ:tandem VHHs E07-A05 (a), IL-10Rα:IL-10Rβ:IL-10 (b, PDB ID: 6X93), IL-22Rα:IL-10Rβ:IL-22 (c, PDB ID: 6WEO) and IFN-λR1:IL-10Rβ:IFN-λ (d, PDB ID: 5T5W), with close-up views of the IL-10Rβ binding site.
Extended Data Fig. 6 Receptor geometry and molecular architecture determine msIL-10R agonist activity and selectivity.
a-c, Indicated null mutants (a) of the msIL-10R agonist were added to human PBMCs for 15 min, and monocyte pSTAT3 levels were quantified by flow cytometry (b). (c) TNF-α, IL-6, and IL-1β concentrations in supernatants from LPS-stimulated human PBMCs treated with 0.15 nM IL-10 or the indicated msIL-10R agonist null mutants. Each dot represents an individual donor. Statistical comparisons were performed using one-way ANOVA with Dunnett’s multiple comparisons test. *p < 0.05, **p < 0.01; ***p < 0.001; ****p < 0.0001. d, STAT3-luciferase reporter activity in HEK293T cells stably expressing IL-10Rα and IL-10Rβ following stimulation with E07-A05/E07-A05 tetravalent antibodies containing the indicated GS linker lengths. Responses were normalized to 10 nM recombinant IL-10 (n = 2 biological replicates). e, STAT3-luciferase reporter activity in HEK293T cells stably expressing IL-10Rα and IL-10Rβ following stimulation with E07-A05/E07-A05 (msIL-10R agonist), the inverted A05-E07/A05-E07 construct, or the symmetric A05-A05/E07-E07 construct. Reporter activity was normalized to the response induced by 10 nM recombinant IL-10 (n = 3 biological replicates). f, IL-6 concentrations in supernatants from LPS-stimulated PBMCs treated with E07-A05/E07-A05 (msIL-10R agonist) or the symmetric A05-A05/E07-E07 construct (n = 4 donors). g, Left, IFN-γ concentrations in supernatants of activated CD8+ T cells treated with IL-10 Fc, E07-A05/E07-A05 (msIL-10R agonist), or the symmetric E07-E07/A05-A05 construct (n = 3 donors). Right, pSTAT3 MFI in CD8+ T cells treated with the indicated molecules. Responses were normalized to those induced by 10 nM IL-10 (n = 4 donors). Data are mean ± standard deviation (s.d.); dots represent biological replicates. The diagram in a was created using BioRender; Yi, T. https://biorender.com/juf8dyp (2026).
Extended Data Fig. 7 TYK2 inhibition abrogates msIL-10R agonist signalling and anti-inflammatory function in mouse BMDMs.
a, pSTAT3 MFI in BMDMs from humanized IL-10RA/RB mice left untreated (unstim) or treated with 10 nM IL-10 or msIL-10R agonist in the presence of DMSO, the TYK2 inhibitor (Zasocitinib, Zas), the JAK1 transphosphorylation inhibitor (VVD-118313, VVD), or both inhibitors (n = 3 biological replicates). b,c, TNF-α (b) and IL-6 (c) concentrations in supernatants from LPS-stimulated BMDMs derived from humanized IL-10RA/RB mice treated with IL-10 or msIL-10R agonist in the presence of DMSO, zasocitinib, VVD-118313, or both inhibitors (n = 5 or 6 biological replicates pooled from two experiments). d, Immunoblot analysis of pSTAT3, STAT3, and GAPDH in BMDMs from humanized IL-10RA/RB mice left untreated (none) or treated with msIL-10R agonist in the presence of DMSO vehicle, JAK1 inhibitor (upadacitinib, Upa) or JAK1 transphosphorylation inhibitor (VVD-118313, VVD). n = 2 replicate immunoblots. Data are mean ± standard deviation (s.d.); dots represent biological replicates. Statistical comparisons were performed using one-way ANOVA with Dunnett’s multiple-comparison test. ****P < 0.0001; ns, not significant.
Extended Data Fig. 8 Impact of IL-10RA or IL-10RB overexpression on IL-10, msIL-10R agonist, and IL-10 monomer response in activated CD8+ T cells.
a, IL-10Rα and IL-10Rβ surface copy numbers in activated CD8+ T cells following lentiviral overexpression (OE) of IL10RA, IL10RB, or both IL-10RA and IL-10RB (n = 4 donors). b, Representative histograms of IL-10Rα and IL-10Rβ expression (left two panels, respectively) and pSTAT3 staining following stimulation with vehicle control, IL-10, or the msIL-10R agonist (right three panels) in CD8+ T cells transduced with IL-10Rα alone, IL-10Rβ alone, or both IL-10Rα and IL-10Rβ. c, Representative histograms of IL-10Rα and IL-10Rβ expression (left two panels, respectively) and granzyme B staining following stimulation with vehicle control, IL-10, or msIL-10R agonist (right three panels) in CD8+ T cells transduced with IL-10Rα alone, IL-10Rβ alone, or both IL-10Rα and IL-10Rβ. d, Representative histograms of IL-10Rα and IL-10Rβ expression (left two panels, respectively) and pSTAT3 staining following stimulation with vehicle control, IL-10, or IL-10 monomer (right three panels) in CD8+ T cells transduced with IL-10Rα alone, IL-10Rβ alone, or both IL-10Rα and IL-10Rβ. e, Representative histograms of IL-10Rα and IL-10Rβ expression (left two panels, respectively) and granzyme B staining following stimulation with vehicle control, IL-10, or IL-10 monomer (right three panels) in CD8+ T cells transduced with IL-10Rα alone, IL-10Rβ alone, or both IL-10Rα and IL-10Rβ. Panel c and e are from the same experiment. f, pSTAT3 MFI in CD8+ T cells treated with vehicle control (none), IL-10, msIL-10R agonist, or IL-10 monomer in the presence or absence of JAK1 overexpression (n = 3 donors). g, Granzyme B MFI in CD8+ T cells treated with vehicle control (none), IL-10, msIL-10R agonist, or IL-10 monomer in the presence or absence of JAK1 overexpression (n = 3 donors). h, pSTAT3 MFI in CD8+ T cells treated with vehicle control (none), IL-10, msIL-10R agonist, or IL-10 monomer in the presence or absence of TYK2 overexpression (n = 3 donors). i, Granzyme B MFI in CD8+ T cells treated with vehicle control (none), IL-10, msIL-10R agonist, or IL-10 monomer in the presence or absence of TYK2 overexpression (n = 3 donors). All data are mean ± standard deviation (s.d.); dots represent biological replicates.
Extended Data Fig. 9 T/NK selective IL-10R agonist preferentially signals through T and NK cells.
a, Schematic of engineered T cell/NK cell selective IL-10R agonists. b, pSTAT3 MFI of CD4+ T cells (left) and NK cells (right) following dose-response stimulation with isotype control, IL-10 Fc, or two T/NK cell selective agonists (n = 3 donors). c, Representative flow cytometry histograms of pSTAT3, pSTAT1, and pSTAT5 staining in T cells stimulated with PBS (ctrl), IL-10 Fc, or the indicated T/NK-selective IL-10R agonists (n = 3 donors). d, Schematic representation of T/NK-selective IL-10R agonist formats, including in cis AG/AG, trans A-G, and trans AA-GG molecules. e, pSTAT3 MFI in CD8+ T cells stimulated with the indicated molecules shown in d. Responses were normalized to those induced by IL-10. f, Intracellular granzyme B MFI in activated CD8+ T cells stimulated with the indicated molecules shown in d. Responses were normalized to those induced by IL-10. The diagrams in a and d were created using BioRender; Yi, T. https://biorender.com/juf8dyp (2026).
Extended Data Fig. 10 Humanized msIL-10R agonist exhibits IgG-like plasma half-life without IL-18 induction or haematological toxicity.
a, Mean plasma concentrations of human IgG1 following a single intravenous dose of the indicated molecules in cynomolgus monkeys (n = 2 animals per group). b, Mean anti-human IgG MFI on peripheral blood monocytes from cynomolgus monkeys treated with the indicated molecules (n = 2 animals per group). c, TNF-α concentrations in supernatants from ex vivo LPS-stimulated whole blood collected at the indicated time points after dosing. Bars indicate means and dots represent individual biological replicates. Pre-dose samples include blood collected 14 and 2 days before dosing. At each time point, two independent whole blood samples from each cynomolgus monkey were stimulated with LPS and analysed separately (n = 2 animals). Statistical comparisons were performed using one-way ANOVA with Dunnett’s multiple comparison test. ***p < 0.001; ****p < 0.0001. d, Serum IL-18 concentrations in cynomolgus monkeys over time (mean; n = 2 animals per group). e, Red blood cell (RBC) count, haematocrit, and platelet count normalized to pre-dose baseline values after administration of the indicated molecules (Line indicates the mean value; each dot represents an individual biological replicate; n = 2 animals per group).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Canaria, D.A., Nguyen, T.T.T., Huang, H. et al. Engineered TYK2 dependence enables myeloid-selective IL-10 receptor agonism. Nature (2026). https://doi.org/10.1038/s41586-026-11176-1
Received: 11 February 2026
Accepted: 17 September 2026
Published: 14 October 2026
Version of record: 14 October 2026
DOI: https://doi.org/10.1038/s41586-026-11176-1
来源:Nature 综合主刊 · nature.com